Selecting endpoints to use in preclinical trials in a mouse model of Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain, that leads to cognitive impairment. AD is characterised by the accumulation of β-amyloid peptides and tau proteins into amyloid plaques and neurofibrillary tangles. AD currently has no cure, however promising research and treatment is underway. The aim of this work is to determine appropriate endpoints to use in a preclinical trial of 5xFAD mouse model of AD. In this thesis, I demonstrate endpoints appropriate to use for preclinical trials and appropriate group and effect sizes.